A phase II trial using a universal GM-CSF [granulocyte-macrophage colony-stimulating factor]-producing and CD40L-expressing bystander cell line (GM. CD40L) in the formulation of autologous tumor cell-based vaccines for patients with malignant melanoma

Trial Profile

A phase II trial using a universal GM-CSF [granulocyte-macrophage colony-stimulating factor]-producing and CD40L-expressing bystander cell line (GM. CD40L) in the formulation of autologous tumor cell-based vaccines for patients with malignant melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2015

At a glance

  • Drugs CD40L GVAX (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Nov 2012 Primary endpoint added as reported by ClinicalTrials.gov.
    • 15 Nov 2012 Additional lead trial centres added as reported by ClinicalTrials.gov record.
    • 27 Dec 2007 The expected completion date for this trial is now 1 Oct 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top